Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.
| Revenue (Most Recent Fiscal Year) | $80.00M |
| Net Income (Most Recent Fiscal Year) | $-9.73M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.72 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -0.64% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -31.05% |
| Return on Assets (Trailing 12 Months) | -28.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 24.42 |
| Quick Ratio (Most Recent Fiscal Quarter) | 28.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.96 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.16 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.22 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 54.09M |
| Free Float | 50.31M |
| Market Capitalization | $369.45M |
| Average Volume (Last 20 Days) | 0.95M |
| Beta (Past 60 Months) | 2.47 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 89.83% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |